

# CEPI – Coalition for Epidemic Preparedness Innovations

CEPI – a model for funding other initiatives and areas



CEPI


BILL & MELINDA  
GATES foundation





Foto: Daniel Berehulak, The New York Times

# Testing of an Ebola vaccine – a successful but suboptimal story



# The start: A need for global solutions

ADVANCE UNEDITED COPY

## Protecting Humanity from Future Health Crises

Report of the  
High-level Panel on the Global Response to Health Crises

25 January 2016

## Report of the Ebola Interim Assessment Panel



## AN R&D BLUEPRINT FOR ACTION TO PREVENT EPIDEMICS PLAN OF ACTION MAY 2016



Outcome document  
Financing of R&D Preparedness and Response to Epidemic  
Emergencies  
October 29-30, 2015  
Oslo, Norway

### Background

This Outcome document summarizes discussions that took place during the Oslo consultation on *Financing of R&D Preparedness and Response to Epidemic Emergencies* (October 29-30, 2015). It reflects views expressed and the discussion that took place, but does not necessarily reflect all interventions. Names of representatives of countries and organizations participating in the Oslo consultation on Financing can be found on the webpage of the Norwegian Institute of Public Health. Stakeholders represented included government, industry, NGOs and academia as well as charitable foundations and other relevant actors. The consultation was jointly organized by WHO and the Norwegian Institute of Public Health and hosted by the Norwegian Institute of Public Health.

## THE LANCET

Online First Current Issue All Issues Special Issues Multimedia Information for Authors

All Content Search Advanced Search

Access provided by The Wellcome Trust

< Previous Article Volume 386, No. 10009, p2204-2221, 28 November 2015 Next Article >

Health Policy

### Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to Ebola

Dr Sueerie Moon, PhD, DPH, Sophie Delaunay, MSc, Prof Eric Goosby, MD, Prof Leung, MD, J Stephen Morris, Benjamin Hawkins, PhD, Lisa...  
Published Online: 22 November 2015

## NATIONAL ACADEMY OF MEDICINE

ABOUT THE NAM PROGRAMS INITIATIVES PERSPECTIVES NEWS SUPPORT MEMBER RESOURCES

## Global Health Risk Framework

*The Neglected Dimension of Global Security: A Framework to Counter Infectious Disease Crises*

Download the Report

## The NEW ENGLAND JOURNAL of MEDICINE

HOME ARTICLES & MULTIMEDIA ISSUES SPECIALTIES & TOPICS FOR AUTHORS CME

### Perspective

#### Establishing a Global Vaccine-Development Fund

Stanley A. Plotkin, M.D., Adel A.F. Mahmoud, M.D., Ph.D., and Jeremy Farrar, M.D., Ph.D.  
N Engl J Med 2015; 373:297-300 | July 23, 2015 | DOI: 10.1056/NEJMp1506020

Comments open through July 29, 2015


Article References Citing Articles (8) Comments (2) Metrics

# World Economic Forum, Davos 19 Jan



# CEPI's First Investors

Total investments (\$m)



In addition: EC plans to co-fund with up to €250 mill

# What is CEPI?

- CEPI is a partnership of public, private, philanthropic and civil society organisations
- CEPI will *stimulate, finance and coordinate* vaccine development
  - against priority threats,
  - particularly when development is unlikely to occur through market incentives alone.

# Strategic objectives

1

Preparedness

2

Response speed


3

Predictability

4

Equity

# CEPI's end-to-end gap-filling role: a sustainable partnership approach



# CEPI's operating principles conceptualized in Business Plan

- Adhering to equitable access principles of affordable pricing and availability of vaccines by priority populations in emergencies
- Securing industry participation through predictable pathways and risk/benefit sharing arrangements and handling of liability through indemnification
- Supporting data sharing and sample sharing mechanisms, and long-term development of regional capabilities for epidemic vaccine preparedness

# How will CEPI work?

- CEPI will move vaccine candidates through late preclinical studies to proof of concept and safety in humans before epidemics begin
  - larger effectiveness trials can begin swiftly in an outbreak
  - small stockpiles are ready for potential emergency use
- CEPI will build technical platforms and institutional capacities that can be rapidly deployed against new and unknown pathogens

# CEPI's Initial Target Diseases

**MERS**

**Lassa**

**Nipah**

Starting point: WHO's list of priority pathogens defined by the WHO R&D Blueprint

CEPI's SAC chose three initial diseases based expected

- public health impact
- risk of an outbreak occurring
- feasibility of vaccine development

# CEPI's Calls for Proposals for Vaccine Development

## 1. MERS, Lassa-fever and Nipah virus

*Step 1: Deadline 8 March 2017*

*Step 2: July 2017*

## 2. Vaccine platform technology


*Deadline 17 October 2017*

## 3. Ebola

*Pending dialogue with scientific groups to define specific need*

*Autumn 2017*


# Regulatory scientific challenges – Working Group



- Clarify current gaps in scientific knowledge that makes it challenging to use non-traditional regulatory pathways for the approval of CEPI and Ebola vaccines in the absence of clinical efficacy data.
- Need a process to allow regulators and vaccine developers discuss what could be attempted to overcome these issues

# G20 - calling for an international collaboration hub for AMR R&D

- The Global Antimicrobial Resistance (AMR) Collaboration Hub
  - ✓ co-ordinate efforts to invigorate antimicrobial research
  - ✓ encourage global involvement and investment
- The scope of work
  - ✓ all stages of the antimicrobial development pipeline
  - ✓ vaccines, alternative therapies and new diagnostic tools



**G20 GERMANY 2017**  
HAMBURG

**G20 Leaders' Declaration**

**Shaping an interconnected world**


# Suggested international AMR policy actions




- Strengthening surveillance and monitoring systems in the community and hospitals
- Fostering research and development of new antimicrobial therapies, including improved biosecurity measures in agriculture
- Need for both “push” and “pull” mechanisms
- Access and sustainable use are integral
- **Global collaboration and financing necessary**
- Enhancing coordination between countries to develop a true global action plan to tackle AMR
- Adopt a broader ‘one-health’ approach covering human health, agriculture and the environment



# Significant “push” progress – R&D development



# “Pull” is missing – to obtain a sustainable market




# Neglected Tropical Diseases

- Historically overlooked diseases
- Neglected at the community, national, and international levels
- Endemic in many resource-poor populations and developing countries
- WHO has specifically identified 20 core NTDs
- Poverty in particular is a key social determinant of uncontrolled NTD spread
- Regulatory scientific challenges
- Clinical trial capacity in endemic setting



# DNDi - non-profit drug research and development (R&D) organization



# Science Dialogue Forum 22 March

**«CEPI is an extremely important contribution to global health.»**

*German Chancellor  
Angela Merkel*



A young girl with braided hair, wearing a pink shirt, is smiling broadly and holding a white sign. The sign has the text "THANK YOU SCIENCE!" written on it in black, hand-drawn capital letters. The background shows a clothesline with various items of clothing hanging on it, and some green foliage. The scene is outdoors, likely in a rural or developing area.

“THANK  
YOU  
SCIENCE!”